VICTOZA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
VICTOZA
Date registered
Evaluation commenced
Decision date
Approval time
193 working days (255)
Active ingredients
liraglutide
Registration type
EOI
Indication
VICTOZA (solution for injection) is now also indicated for:
- Glycaemic control: VICTOZA is indicated as an adjunct to diet and exercise for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control, as monotherapy when metformin is contraindicated or is not tolerated.
- Prevention of cardiovascular events: In patients where VICTOZA is indicated to improve glycaemic control, VICTOZA is indicated to reduce the risk of cardiovascular events in those at high cardiovascular risk, as an adjunct to standard of care therapy.